Adial Pharmaceuticals reported a $0.59 EPS loss, missing consensus estimate by $0.20, while short interest increased by 92.5% in July.

Adial Pharmaceuticals (NASDAQ: ADIL), a clinical-stage biopharmaceutical firm specializing in addiction & disorder treatments, reported a $0.59 EPS loss for the quarter, falling short of the consensus estimate of $0.39 by $0.20. Its lead product, AD04, is in Phase III clinical trials for alcohol use disorder treatment. Shares traded at $0.97, with a 50-day SMA of $1.12 and a 200-day SMA of $1.40. Short interest increased by 92.5% in July, with 7.2% of shares shorted.

August 15, 2024
6 Articles

Further Reading